Comparison of representative topical corticosteroid preparations (classified according to the US system)

Size: px
Start display at page:

Download "Comparison of representative topical corticosteroid preparations (classified according to the US system)"

Transcription

1 Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s), percent (except as noted) Super-high potency (group ) di, augmented Clobetasol Ointment, optimized Diprolene Lotion Diprolene Gel Diprolene Ointment Temovate Temovate, emollient base Temovate E Gel Temovate Lotion Clobex Foam aerosol Olux-E Foam aerosol (scalp) Olux Shampoo Clobex Solution (scalp) Temovate, Cormax Spray aerosol Clobex Diflucortolone (not available in United States) Ointment, oily cream Nerisone Forte (United Kingdom, others) 0.3 Fluocinonide Vanos Flurandrenolide Tape (roll) Cordran 4 mcg/cm 2 Halobetasol Ointment Ultravate Ultravate High potency (group 2) Lotion Ultravate Amcinonide Ointment Cyclocort, Amcort di Ointment Diprosone, augmented formulation (AF) Diprolene AF Clobetasol Impoyz Desoximetasone Ointment Topicort 0.25 Topicort 0.25 Spray Topicort 0.25 Gel Topicort

2 Diflorasone diacetate Ointment ApexiCon, Florone, emollient ApexiCon E Fluocinonide Ointment Lidex Gel Lidex anhydrous Lidex Solution Lidex Halcinonide Ointment Halog High potency (group 3) Halog Amcinonide Cyclocort, Amcort Lotion Amcort di, hydrophilic emollient Diprosone Ointment Valisone Foam Luxiq 2 Desoximetasone Topicort LP Diflorasone diacetate Florone Diflucortolone (not available in United States) Fluocinonide, oily cream, ointment aqueous emollient Nerisone (Canada, United Kingdom, others) Lidex-E Fluticasone Ointment Cutivate Mometasone furoate Ointment Elocon Medium potency (group 4) di Ointment Kenalog 0.5 Triderm, Aristocort HP 0.5 Spray Sernivo Clocortolone pivalate Cloderm Fluocinolone Ointment Synalar Flurandrenolide Ointment Cordran Ointment Westcort 0.2 Mometasone furoate Elocon Lotion Elocon Solution Elocon Kenalog Ointment Kenalog

3 Lower-mid potency (group 5) di Aerosol spray Kenalog 0.2 mg per 2 second spray Lotion Diprosone Beta-Val, Valisone Desonide Ointment DesOwen, Tridesilon Fluocinolone Gel Desonate Synalar Flurandrenolide Cordran Lotion Cordran Fluticasone butyrate Cutivate Lotion Cutivate Ointment Locoid Locoid, Locoid Lipocream Lotion, spray Cortizone 0 maximum Lotion Locoid Solution Locoid probutate Pandel Westcort 0.2 Prednicarbate, emollient Dermatop Ointment Dermatop Low potency (group 6) Alclometasone di Lotion Kenalog Ointment Kenalog Ointment Aclovate Aclovate Lotion Beta-Val, Valisone Desonide DesOwen, Tridesilon Lotion DesOwen, LoKara Fluocinolone Foam Verdeso Synalar Solution Synalar Shampoo Capex Oil (scalp) Derma-Smoothe/FS Scalp

4 Least potent (group 7) (base, 2%) Oil (body) Derma-Smoothe/FS Body Kenalog, Aristocort Lotion Kenalog Ointment Hytone 2.5 Hytone, Nutracort 2.5 Lotion Hytone, Ala Scalp, Scalacort 2.5 or 2 Solution Texacort 2.5 (base, <2%) Ointment Cortaid, Hytone, Nutracort Cortaid, Hytone, Synacort Lotion Aquanil HC, Sarnol- HC, Cortizone 0 Spray Cortaid Solution Cortaid, Noble, Scalp relief Ointment Cortaid 0.5 Cortaid 0.5 acetate with pramoxine % combination Ointment Pramosone or 2.5 Lotion Pramosone, Analpram-HC Pramosone, Analpram-HC or 2.5 or 2.5 Aerosol foam Epifoam US: United States. * Listed by potency according to the US classification system: group is the most potent, group 7 is the least potent. Other countries use a different classification system with only four or five groups. Inactive United States trade name for specific product; brand may be available outside United States. 48% refined peanut oil. Data from:. Lexicomp Online. Copyright Lexicomp, Inc. All Rights Reserved. 2. Tadicherla S, Ross K, Shenefelt D. Topical corticosteroids in dermatology. Journal of Drugs in Dermatology 2009; 2: U.S. Food & Drug Administration Approved Drug Products with Therapeutic Equivalence (Orange Book). Available at: (Accessed on June 8, 207). Graphic Version 46.0

5 GRAPHICS Topical antifungal agents Azoles Drug Dose How supplied* Clotrimazole Twice per day % Ointment % Solution % Econazole Once per day (twice per day for candidiasis) % Foam % Efinaconazole Once per day Solution 0% Ketoconazole Once per day (shampoo is usually one use) 2% Shampoo 2% (% shampoo is available overthe-counter) Gel 2% Foam 2% Luliconazole Once per day % Miconazole Twice per day 2% Ointment 2% Solution 2% Lotion 2% Powder 2% Aerosol solution 2% Aerosol powder 2% Oxiconazole Once to twice per day % Lotion % Sertaconazole Twice per day 2% Sulconazole Once or twice per day % Allylamines Solution % Naftifine Once per day (cream), twice per day (gel) % 2% Gel % Gel 2% Terbinafine Once to twice per day % Benzylamine Gel % Spray solution % Butenafine Once per day (twice per day for tinea pedis) % Polyene: Treats Candida infections only Nystatin Two to three times per day 00,000 units/gram

6 Other Ointment 00,000 units/gram Powder 00,000 units/gram Ciclopirox Twice per day 0.77% Gel 0.77% Suspension 0.77% Shampoo % Solution 8% Tolnaftate Twice per day % Powder % Aerosol: Liquid % Powder % Solution % * Preparations available in United States and some other countries. Azoles have activity against dermatophytes, tinea versicolor, and Candida. Sulconazole, oxiconazole, and luliconazole may be less effective for Candida infection than other azoles. Available in over-the-counter (nonprescription) preparations in the United States and some other countries. Indicated for onychomycosis. Can treat Candida in addition to dermatophytes and tinea versicolor but may be less effective than azoles and ciclopirox for Candida infection. Treats dermatophytes, tinea versicolor, and Candida. Does not treat Candida; less effective than other options for dermatophytes. Prepared with data from: US Food & Drug Administration (FDA) approved product information. US National Library of Medicine. (Available online at: Graphic 7648 Version.0

Comparison of representative topical corticosteroid preparations (classified according to the US system)

Comparison of representative topical corticosteroid preparations (classified according to the US system) Comparison of representative topical corticosteroid preparations (classified according to the US system) Potency group* Corticosteroid Vehicle type/form Trade names (United States) Available strength(s),

More information

The Medical Letter. on Drugs and Therapeutics

The Medical Letter. on Drugs and Therapeutics The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:

More information

Pharmacy Benefit Determination Policy

Pharmacy Benefit Determination Policy Policy Subject: Atopic Dermatitis Agents Policy Number: SHS PBD18 Category: Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual HMO/POS PPO ASO s:

More information

Drug Class Literature Scan: Topical Steroids

Drug Class Literature Scan: Topical Steroids Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Provider Bulletin June 2017 The formulary changes listed in the table below apply to all Anthem HealthKeepers Plus patients. These changes were reviewed and approved at the first quarter Pharmacy and Therapeutics

More information

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan

Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Michigan Pharmacy and Therapeutics Committee September 9, 2014 at 6:00 PM Kellogg Center, East Lansing, Michigan Agenda: Introductions Approval of Minutes of July 8, 2014 Meeting P & T Business Review

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.25 Subject: Eucrisa Page: 1 of 6 Last Review Date: September 15, 2017 Eucrisa Description Eucrisa

More information

Eucrisa. Eucrisa (crisaborole) Description

Eucrisa. Eucrisa (crisaborole) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Eucrisa Page: 1 of 7 Last Review Date: June 22, 2018 Eucrisa Description Eucrisa (crisaborole)

More information

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL

DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. UNIFORM FORMULARY REVIEW PROCESS Under 10 United States Code

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2116-3 Program Prior Authorization/Medical Necessity Medications Dupixent (dupilumab) P&T Approval Date 1/2017, 5/2017, 7/2017

More information

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018

Medication Policy Manual. Topic: Dupixent, dupilumab Date of Origin: March 10, Committee Approval: March 10, 2017 Next Review Date: May 2018 Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru493 Topic: Dupixent, dupilumab Date of Origin: March 10, 2017 Committee Approval: March 10, 2017

More information

Effective for all members on August 1, 2017

Effective for all members on August 1, 2017 August 2017 Pharmacy Formulary Change Notice BlueChoice HealthPlan Medicaid is here to help you stay on top of your health care. We want to tell you about some upcoming changes to your Preferred Drug List

More information

The safety and effectiveness of Dupixent in pediatric patients have not been established (1).

The safety and effectiveness of Dupixent in pediatric patients have not been established (1). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.30 Subject: Dupixent Page: 1 of 6 Last Review Date: September 15, 2017 Dupixent Description Dupixent

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Dupixent GENERIC NAME dupilumab MANUFACTURER Regeneron DATE OF APPROVAL March 28, 2017 PRODUCT LAUNCH DATE First week of April 2017 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Enstilar, Sernivo, Taclonex) Reference Number: CP.CPA.255 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.HNMC.208 Effective Date: 04.11.17 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy

More information

Connecticut Medicaid P&T Meeting Minutes December 2, 2010

Connecticut Medicaid P&T Meeting Minutes December 2, 2010 Connecticut Medicaid P&T Meeting Minutes December 2, 2010 The meeting started at 6:34 pm Attendance Present Members: Carl Sherter, MD Peggy Manning Memoli, Pharm D Eric Einstein, MD Charles Thompson, MD

More information

Children s Hospital Of Wisconsin

Children s Hospital Of Wisconsin Children s Hospital Of Wisconsin Co-Management Guidelines To support collaborative care, we have developed guidelines for our community providers to utilize when referring to, and managing patients with,

More information

Pharmacologic Treatment of Atopic Dermatitis

Pharmacologic Treatment of Atopic Dermatitis J KMA Pharmacotherapeutics Pharmacologic Treatment of Atopic Dermatitis Chun Wook Park, MD Department of Dermatology, Hallym University College of Medicine E mail : dermap@paran.com J Korean Med Assoc

More information

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Technology Appraisals and Guidance Information Services Static List Review (SLR) report Title and TA publication number of static topic: Final decision:

More information

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD)

Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) Diagnosis: ATOPIC DERMATITIS (AD) Texas Children's Hospital Dermatology Service PCP Referral Guidelines- Atopic Dermatitis (AD) PATIENT ADVICE: Unfortunately, there is no cure for atopic dermatitis, so

More information

84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents

84:00. Skin and Mucous Membrane Agents. 84:00 Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents Skin and Mucous Membrane Agents COMPOUND PRESCRIPTION 00000999119 00000999112 COMPOUND - RETINOIC ACID (TRETINOIN) () MISCELLANEOUS COMPOUND To be used when the compound

More information

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:

Clinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date: Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal

More information

Topical Immunomodulators

Topical Immunomodulators Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Topical Immunomodulators Clinical Edit Information Included in this Document Topical Immunomodulators Elidel and Protopic 0.03%

More information

Clinical pharmacology review for primary health care providers: II. Steroids

Clinical pharmacology review for primary health care providers: II. Steroids TCP 2015;23(1):15-20 http://dx.doi.org/10.12793/tcp.2015.23.1.15 Clinical pharmacology review for primary health care providers: II. Steroids TUTORIAL Seunghoon Han* Department of Clinical Pharmacology

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Dupixent) Reference Number: CP.PHAR.336 Effective Date: 05.01.17 Last Review Date: 02.19 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder

More information

LUZU (luliconazole) external cream

LUZU (luliconazole) external cream LUZU (luliconazole) external cream Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Dupixent (dupilumab)

Dupixent (dupilumab) Dupixent (dupilumab) Line(s) of Business: HMO; PPO; QUEST Integration Effective Date: TBD POLICY A. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered

More information

2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014

2015 Medicare Step Therapy Criteria. Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 2015 Medicare Step Therapy Criteria Last Modified: 12/31/2014 Last Submitted to CMS: 10/29/2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...

More information

Managing and Minimizing Flare-ups in Atopic Dermatitis

Managing and Minimizing Flare-ups in Atopic Dermatitis Managing and Minimizing Flare-ups in Atopic Dermatitis Importance of the skin barrier & how commonly used drugs are impacting it Dr. Benjamin Barankin, MD FRCPC Medical Director & Founder of Toronto Dermatology

More information

Drug Formulary Update, April 2017 Commercial and State Programs

Drug Formulary Update, April 2017 Commercial and State Programs Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

79 C. Michael Davenport Blvd. Suite A Frankfort, KY August 5, Dear Kentucky Medicaid Provider:

79 C. Michael Davenport Blvd. Suite A Frankfort, KY August 5, Dear Kentucky Medicaid Provider: 79 C. Michael Davenport Blvd. Suite A Frankfort, KY 40601 August 5, 2010 Dear Kentucky Medicaid Provider: Please be advised that the Department for Medicaid Services is making changes to the Kentucky Medicaid

More information

BB&T 2014 Step Therapy Program Drug List

BB&T 2014 Step Therapy Program Drug List BB&T 2014 Step Therapy Program Drug List For the drug classifications listed in the table below, members must have tried one Step One medication within the past 130 days before a Step Two medication will

More information

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019

ANTIEMETICS STEP. Step Therapy Requirements Effective April 1, 2019 Step Therapy Requirements Effective April 1, 2019 ANTIEMETICS STEP Sancuso 3.1 mg/24 hour transdermal patch Zuplenz 4 mg oral soluble film Zuplenz 8 mg oral soluble film COVERAGE OF CERTAIN BRAND NAME

More information

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017

ALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Select Drug Quantity Management

Select Drug Quantity Management Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided

More information

Medication Quick Reference

Medication Quick Reference Medication Quick Reference Topical steroids CLASS 1 SUPERPOTENT Betamethasone dipropionate Diprolene O/G 0.05% 15, 50 g Clobetasol propionate Temovate O/Cr 0.05% 15, 30, 45 g Temovate S 0.05% 25, 50 ml

More information

2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS:

2014 Medicare Step Therapy Criteria. Last Modified: Last Submitted to CMS: 2014 Medicare Step Therapy Criteria Last Modified: 09.30.2014 Last Submitted to CMS: 09.02.2014 1 Table of Contents AMITIZA, LINZESS... 3 ANTIDEPRESSANTS - Viibryd / Pexeva / Pristiq / Desvenlafaxine...

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 10/28/2014 Effective date: 11/15/2014 Therapeutic Classes reviewed: Pulmonary arterial hypertension

More information

NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)*

NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)* NHA Automatic Therapeutic Interchange Policy (Updated July 23, 2015)* The following interchanges have been implemented to ensure rational use of select drugs, to decrease drug expenditures, and to allow

More information

2016 PRESCRIPTION DRUG LIST UPDATES

2016 PRESCRIPTION DRUG LIST UPDATES 2016 PRESCRIPTION DRUG LIST UPDATES Evergreen Health 1 st Quarter Below are key updates to the four-tier EHB Prescription Formulary, effective January 1, 2016. Please consult the full formulary for more

More information

Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis.

Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. Abstract. OBJECTIVE--To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment of tinea pedis. DESIGN-- Multicentre, double blind parallel group study. SETTING--32

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions PHARMACY SERVICES High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013

DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013 DECISION PAPER DEPARTMENT OF DEFENSE PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS August 2013 I. UNIFORM FORMULARY DRUG CLASS REVIEWS A. Corticosteroid Immune Modulators (Topical Steroids) Background

More information

High-Cost Drug Exclusions

High-Cost Drug Exclusions Pharmacy Services High-Cost Exclusions The high cost medications listed below are excluded from coverage because lower cost similar alternatives are available. To help you get the best health benefit at

More information

STEP THERAPY. Cigna Pharmacy Management. What is Step Therapy?

STEP THERAPY. Cigna Pharmacy Management. What is Step Therapy? STEP THERAPY Cigna Pharmacy Management What is Step Therapy? Prescription medications cost a lot of money. At Cigna, we get that. That s why we ve created a program that helps save you money and stay healthy.

More information

Designing a Campaign On Topical steroids misuse

Designing a Campaign On Topical steroids misuse Ministry Of Higher Education And Scientific Research University Of Al-Qadysiah College Of Pharmacy Designing a Campaign On Topical steroids misuse By: Hussein A. Abdulwahab Ali H. Abd Zaid Supervised By:

More information

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy

Literature Scan: Topical Corticosteroids. Month/Year of Review: March 2015 Date of Last Review: March 2013 Source Document: OSU College of Pharmacy Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Below is a summary of the PDL changes that will be effective May 1, All other agents in these classes will retain their current PDL listing.

Below is a summary of the PDL changes that will be effective May 1, All other agents in these classes will retain their current PDL listing. STATE OF TENNESSEE DIVISION OF TENNCARE 310 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise you of information regarding the TennCare Pharmacy Program. Please forward or copy the

More information

Step Therapy Medications

Step Therapy Medications Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on

More information

Category Second-Line (Targeted) First-Line (Alternative) Most Common Indication

Category Second-Line (Targeted) First-Line (Alternative) Most Common Indication Step therapy requires trial of a step-one drug before a step-two drug will be covered under the plan. If your medical condition warrants, share this list with your doctor and ask her or him to prescribe

More information

Skin Manifestations of Allergy

Skin Manifestations of Allergy Dermatologic Manifestations of Allergy William Reisacher MD FACS FAAOA Assistant Professor Weill Cornell Medical College Skin Manifestations of Allergy Atopic dermatitis (atopic eczema, eczema) Contact

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018 Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

Drugs dermatological conditions II

Drugs dermatological conditions II MMS Pharmacology Lecture 5 Drugs dermatological conditions II Dr Sura Al Zoubi 1 TOPICAL CORTICOSTEROIDS Corticosteroids (glucocorticoids) have immunosuppressive and antiinflammatory properties. Topical

More information

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018

ALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018 Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell

Fungi are eukaryotic With rigid cell walls composed largely of chitin rather than peptidoglycan (a characteristic component of most bacterial cell Antifungal Drugs Fungal infections (Mycoses) Often chronic in nature. Mycotic infections may be superficial and involve only the skin (cutaneous mycoses extending into the epidermis) Others may penetrate

More information

2019 PacificSource Health Plans Step Therapy Criteria. Last Modified: 02/22/2019 (All criteria reviewed at least once per year)

2019 PacificSource Health Plans Step Therapy Criteria. Last Modified: 02/22/2019 (All criteria reviewed at least once per year) 2019 PacificSource Health Plans Step Therapy Criteria Last Modified: 02/22/2019 (All criteria reviewed at least once per year) Table of Contents ACTICLATE... 3 AMITIZA/LINZESS... 4 ANTIDIABETICS Farxiga,

More information

Outline. Case 1 2/23/2012

Outline. Case 1 2/23/2012 Outline Lindy P. Fox, MD Associate Professor Director, Hospital Consultation Service Department of Dermatology University of California, San Francisco Part 1: Approach to the itchy patient Eczemas Fungal

More information

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP

ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP ATOPIC DERMATITIS: PATHOPHYSIOLOGY AND PHARMACOLOGY OF MANAGEMENT PEGGY VERNON, RN, MA, C-PNP, DCNP, FAANP Disclosures There are no financial relationships with commercial interests to disclose Ay unlabeled/unapproved

More information

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION

LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION LABEL NAME CHANGE EFFECTIVE DATE ARCALYST 220 MG INJECTION Added Prior Authorization 7/1/17 CORLANOR 5 MG TABLET Added Prior Authorization 7/1/17 CORLANOR 7.5 MG TABLET Added Prior Authorization 7/1/17

More information

Pharmaceutical and Therapeutics Committee

Pharmaceutical and Therapeutics Committee Earl Ray Tomblin Governor STATE OF WEST VIRGINIA DEPARTMENT OF HEALTH AND HUMAN RESOURCES Bureau for Medical Services Pharmacy Services 350 Capitol Street Room 251 Charleston, West Virginia 25301-3706

More information

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012

UnitedHealthcare Community Plan PDL Modifications. Added as an alternative agent for the 9/1/ /1/2012 Avonex Pen Interferon beta-1a Added as alternative dosing formulation for the treatment of multiple sclerosis. Prior Korlym Mifepristone Added as alternative agent to control hyperglycemia secondary to

More information

Abbreviated Class Update: Topical Antifungal Agents. Month/Year of Review: March 2014 Date of Last Review: March 2013

Abbreviated Class Update: Topical Antifungal Agents. Month/Year of Review: March 2014 Date of Last Review: March 2013 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

UnitedHealthcare Community Plan PDL Modifications

UnitedHealthcare Community Plan PDL Modifications Lialda Mesalamine Apriso Mesalamine treatment of ulcerative colitis. treatment of ulcerative colitis. Afinitor Disperz Everolimus treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis

More information

Antifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals

Antifungal Agents. Polyenes Azoles Allyl and Benzyl Amines Other antifungals OPTO 6434 General Pharmacology Antifungal Agents Dr. Alison McDermott Room 254 HBSB, Phone 713-743 1974 Email amcdermott@optometry.uh.edu Fall 2015 Reading: Chapter 50 Brody s Human Pharmacology by Wecker

More information

Secretary for Health and Family Services Selections for Preferred Products

Secretary for Health and Family Services Selections for Preferred Products Secretary for Health and Family Services Selections for Preferred Products This is a summary of the final Preferred Drug List (PDL) selections made by the Secretary for Health and Family Services based

More information

The active ingredient of any pharmaceutical

The active ingredient of any pharmaceutical Close Encounters With the Environment Stratum Corneum Absorption Kinetics of 2 Potent Topical Corticosteroid Formulations: A Pilot Study Zoe Diana Draelos, MD Practice Points Fluocinonide concentration

More information

NEW PRODUCTS: HAILEY TM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 mg/20

NEW PRODUCTS: HAILEY TM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 mg/20 DECEMBER 2018 U.S. PRODUCT CATALOG NEW PRODUCTS: HAILEY TM 24 Fe (Norethindrone Acetate and Ethinyl Estradiol Tablets, USP and Ferrous Fumarate Tablets), 1 mg/20 ESTRADIOL VAGINAL INSERTS USP, 10 MCG CLOBETASOL

More information

Report ADDITIONS: Product Brand Agents: Indication. Subcategory. Generic Agents: Gastrointestinal/ Antiemetics

Report ADDITIONS: Product Brand Agents: Indication. Subcategory. Generic Agents: Gastrointestinal/ Antiemetics This report highlights all changes (additions and deletions) to the CVS Caremark Performance Drug List. ADDITIONS: Brand Agents: Diclegis (doxylamine/ pyridoxine delayed release) Gastrointestinal/ Antiemetics

More information

Abbreviated Class Update: Topical Antifungal Agents. Month/Year of Review: September 2014 Date of Last Review: March 2014

Abbreviated Class Update: Topical Antifungal Agents. Month/Year of Review: September 2014 Date of Last Review: March 2014 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

2018 Step Therapy (ST) Criteria

2018 Step Therapy (ST) Criteria 2018 Step Therapy (ST) Criteria Some drugs require step therapy pre-approval. This means that your doctor must have you first try a different drug to treat your medical condition before we will cover a

More information

Drug List exclusions for Blue Cross commercial plans

Drug List exclusions for Blue Cross commercial plans Drug List exclusions for Blue Cross commercial plans The drugs shown below aren t covered on the commercial Blue Cross Blue Shield of Michigan drug lists. In most cases, if you fill a prescription for

More information

2018 Step Therapy FID 18088

2018 Step Therapy FID 18088 2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix

More information

Topical Products with Quantity Limits

Topical Products with Quantity Limits Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Page: 1 of 8 Last Review Date: November 30, 2018 Description Apexicon E Topical Cream 0.05% (diflorasone

More information

(12) United States Patent

(12) United States Patent (12) United States Patent Nichols et al. USOO6830758B2 (10) Patent No.: () Date of Patent: Dec. 14, 2004 (54) PSORIASIS PATCH (75) Inventors: Jane Nichols, Bloomington, MN (US); Teri Buseman, Minnetonka,

More information

Clinical Practice Guideline Superficial Fungal Infection

Clinical Practice Guideline Superficial Fungal Infection Clinical Practice Guideline Superficial Fungal Infection ก ก ก กก ก ก ก ก กก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก ก * ก Superficial fungal infection ก 1. ก (Pityriasis versicolor, Tinea versicolor) 2. ก ก

More information

LABELLING STANDARD ANTIFUNGALS (TOPICAL)

LABELLING STANDARD ANTIFUNGALS (TOPICAL) LABELLING STANDARD ANTIFUNGALS (TOPICAL) I) Description: This labelling standard applies to products in cream, ointment, lotion, gel, powder, spray powder, aerosol liquid, solution, foam, or soap form

More information

If It's Dry, Wet It; If It's Wet, Dry It: A Commonsense Guide to Dermatologic Therapy

If It's Dry, Wet It; If It's Wet, Dry It: A Commonsense Guide to Dermatologic Therapy (+)Catherine A. Marco, MD, FACEP Professor, Director of Medical Ethics Curriculum, University of Toledo College of Medicine If It's Dry, Wet It; If It's Wet, Dry It: A Commonsense Guide to Dermatologic

More information

PQRI Workshop Present Experience and Challenges with the Use of Pharmacodynamics Evaluation of BE of Glucocorticoids Industry Perspective

PQRI Workshop Present Experience and Challenges with the Use of Pharmacodynamics Evaluation of BE of Glucocorticoids Industry Perspective PQRI Workshop Present Experience and Challenges with the Use of Pharmacodynamics Evaluation of BE of Glucocorticoids Industry Perspective Charles Bon and Lindsey Katz Vasoconstrictor assay by McKenzie

More information

CATEGORY IV MONOGRAPH. Athlete's Foot Treatments

CATEGORY IV MONOGRAPH. Athlete's Foot Treatments CATEGORY IV MONOGRAPH Athlete's Foot Treatments I) Description: This monograph applies to products in cream, ointment, lotion, gel, powder, spray powder, aerosol liquid, solution, foam, or soap form intended

More information

Prior Authorization Topical Immunomodulators Elidel and Protopic 0.03%

Prior Authorization Topical Immunomodulators Elidel and Protopic 0.03% Drugs Requiring Label Name GCN ELIDEL 1% CREAM 15348 PROTOPIC 0.03% OINTMENT 12289 TACROLIMUS 0.03% OINTMENT 12289 Clinical Edit Criteria Logic 1. Does the client have a diagnosis of localized skin graft

More information

Antifungal drugs Dr. Raz Muhammed

Antifungal drugs Dr. Raz Muhammed Antifungal drugs 13. 12. 2018 Dr. Raz Muhammed 2. Flucytosine (5-FC) Is fungistatic Is a synthetic pyrimidine antimetabolite Is often used in combination with amphotericin B in the treatment of systemic

More information

About the Editor Gerri S. Hall, Ph.D.

About the Editor Gerri S. Hall, Ph.D. About the Editor Gerri S. Hall, Ph.D. Dr. Hall s professional career has been focused on clinical microbiology: direct clinical activities of various areas such as bacteriology, mycobacteria, STD testing,

More information

OTC PRODUCTS. 4 Gama Benzene HCL 0.1% + Proflavine Hermisulphate 0.1% + Cetrimide 0.45% Cream

OTC PRODUCTS. 4 Gama Benzene HCL 0.1% + Proflavine Hermisulphate 0.1% + Cetrimide 0.45% Cream OTC PRODUCTS SR. No. COMPOSITION Allantoin 0.2% + Dimethicone 1% + Urea 10% + Propylene Glycol 5% + Glyserine 5% + 1 Light Liquid Paraffin 8% Cream (FOOT CREAM) 2 Aquous Cream 3 Cetrimide 0.5% + Chlorhexidine

More information

Topical Corticosteroids

Topical Corticosteroids Topical Corticosteroids Topical Cοrt cοsterοids Editors Howard L Maibach, San Francisco, Calif. Christian Surber, Basel 83 figures and 91 tables, 1992 KARG E R. Basel München Paris London NewYork New

More information

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of drugs by drug class

More information

UnitedHealthcare Community Plan PDL Modifications

UnitedHealthcare Community Plan PDL Modifications Lialda Mesalamine Apriso Mesalamine Afinitor Disperz Everolimus treatment of ulcerative colitis. treatment of ulcerative colitis. treatment of subependymal giant cell astrocytoma (SEGA) with tuberous sclerosis

More information

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS

ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS ADDITIONAL 2017 FORMULARY CHANGES CIGNA COMMERCIAL CUSTOMERS Effective 7/1/2017, Cigna will be making additional formulary changes that may impact customers at your pharmacy. We have included a list of

More information

Drug Prescribing Pattern in Dermatophytosis at the Medical Outpatient Clinic of a Tertiary Healthcare in Karnataka, India

Drug Prescribing Pattern in Dermatophytosis at the Medical Outpatient Clinic of a Tertiary Healthcare in Karnataka, India in Dermatophytosis at the Medical Outpatient Clinic of a Tertiary Healthcare in Karnataka, India Vishal P Giri 1, Om P Giri 2 1 Department of Pharmacology, Teerthanker Mahaveer Medical College and Research

More information

Calgary Zone LTC Formulary Autosubstitution List

Calgary Zone LTC Formulary Autosubstitution List Calgary Zone LTC Formulary Autosubstitution List PURPOSE ASL-01 In order to simplify drug therapy, orders for one medication may be automatically substituted using a different, but therapeutically equivalent

More information

BlueLink TPA FlexRx Updates

BlueLink TPA FlexRx Updates BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%

More information

CHANGES TO YOUR DRUG LIST

CHANGES TO YOUR DRUG LIST CHANGES TO YOUR DRUG LIST More generics and lower-cost brands to help you stay healthy and save money At Cigna, it s our goal to offer you access to coverage for safe, effective and affordable medications.

More information

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Frequency of application of topical corticosteroids for atopic eczema

NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination. Frequency of application of topical corticosteroids for atopic eczema NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Frequency of application of topical corticosteroids for atopic eczema 1 Guidance This appraisal relates to the frequency of application of topical corticosteroids

More information

KPhA s 133 rd Annual Meeting and Trade Show

KPhA s 133 rd Annual Meeting and Trade Show 1 KPhA s 133 rd Annual Meeting and Trade Show KPhA s 133 rd Annual Meeting and Trade Show Be the Critical Link DoubleTree by Hilton Hotel Overland Park, Kansas Dermatology September 21, 2013 Emily Prohaska,

More information

Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice)

Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Using Your ESP* in Pharmacy: How to Improve Treatment Adherence and Patient Outcomes in Psoriasis (*Expanded Scope of Practice) Patient Case Study in Psoriasis Patient Case Study in Psoriasis William Smith,

More information